330 related articles for article (PubMed ID: 29203150)
1. Retroviral and Lentiviral Safety Analysis of Gene-Modified T Cell Products and Infused HIV and Oncology Patients.
Marcucci KT; Jadlowsky JK; Hwang WT; Suhoski-Davis M; Gonzalez VE; Kulikovskaya I; Gupta M; Lacey SF; Plesa G; Chew A; Melenhorst JJ; Levine BL; June CH
Mol Ther; 2018 Jan; 26(1):269-279. PubMed ID: 29203150
[TBL] [Abstract][Full Text] [Related]
2. Absence of Replication-Competent Lentivirus in the Clinic: Analysis of Infused T Cell Products.
Cornetta K; Duffy L; Turtle CJ; Jensen M; Forman S; Binder-Scholl G; Fry T; Chew A; Maloney DG; June CH
Mol Ther; 2018 Jan; 26(1):280-288. PubMed ID: 28970045
[TBL] [Abstract][Full Text] [Related]
3. Replication-Competent Lentivirus Analysis of Vector-Transduced T Cell Products Used in Cancer Immunotherapy Clinical Trials.
Cornetta K; Koop S; Nance E; House K; Duffy L
Methods Mol Biol; 2020; 2086():181-194. PubMed ID: 31707676
[TBL] [Abstract][Full Text] [Related]
4. Engineered T cell therapies.
Field AC; Qasim W
Expert Rev Mol Med; 2015 Nov; 17():e19. PubMed ID: 26530808
[TBL] [Abstract][Full Text] [Related]
5. Safety considerations in vector development.
Kappes JC; Wu X
Somat Cell Mol Genet; 2001 Nov; 26(1-6):147-58. PubMed ID: 12465466
[TBL] [Abstract][Full Text] [Related]
6. [Gene therapy using retrovirus vectors: vector development and biosafety at clinical trials].
Doi K; Takeuchi Y
Uirusu; 2015; 65(1):27-36. PubMed ID: 26923955
[TBL] [Abstract][Full Text] [Related]
7. Optimized Production of Lentiviral Vectors for CAR-T Cell.
Moço PD; de Abreu Neto MS; Fantacini DMC; Picanço-Castro V
Methods Mol Biol; 2020; 2086():69-76. PubMed ID: 31707668
[TBL] [Abstract][Full Text] [Related]
8. Replication competent retrovirus testing (RCR) in the National Gene Vector Biorepository: No evidence of RCR in 1,595 post-treatment peripheral blood samples obtained from 60 clinical trials.
Cornetta K; Yao J; House K; Duffy L; Adusumilli PS; Beyer R; Booth C; Brenner M; Curran K; Grilley B; Heslop H; Hinrichs CS; Kaplan RN; Kiem HP; Kochenderfer J; Kohn DB; Mailankody S; Norberg SM; O'Cearbhaill RE; Pappas J; Park J; Ramos C; Ribas A; Rivière I; Rosenberg SA; Sauter C; Shah NN; Slovin SF; Thrasher A; Williams DA; Lin TY
Mol Ther; 2023 Mar; 31(3):801-809. PubMed ID: 36518078
[TBL] [Abstract][Full Text] [Related]
9. Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes.
Hammill JA; Afsahi A; Bramson JL; Helsen CW
Methods Mol Biol; 2016; 1458():137-57. PubMed ID: 27581020
[TBL] [Abstract][Full Text] [Related]
10. Production of CAR T-cells by GMP-grade lentiviral vectors: latest advances and future prospects.
Poorebrahim M; Sadeghi S; Fakhr E; Abazari MF; Poortahmasebi V; Kheirollahi A; Askari H; Rajabzadeh A; Rastegarpanah M; Linē A; Cid-Arregui A
Crit Rev Clin Lab Sci; 2019 Sep; 56(6):393-419. PubMed ID: 31314617
[TBL] [Abstract][Full Text] [Related]
11. Detection of replication competent retrovirus and lentivirus.
Sastry L; Cornetta K
Methods Mol Biol; 2009; 506():243-63. PubMed ID: 19110631
[TBL] [Abstract][Full Text] [Related]
12. Lentiviral Vectors for T Cell Engineering: Clinical Applications, Bioprocessing and Future Perspectives.
Labbé RP; Vessillier S; Rafiq QA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452392
[TBL] [Abstract][Full Text] [Related]
13. Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV.
Tebas P; Stein D; Binder-Scholl G; Mukherjee R; Brady T; Rebello T; Humeau L; Kalos M; Papasavvas E; Montaner LJ; Schullery D; Shaheen F; Brennan AL; Zheng Z; Cotte J; Slepushkin V; Veloso E; Mackley A; Hwang WT; Aberra F; Zhan J; Boyer J; Collman RG; Bushman FD; Levine BL; June CH
Blood; 2013 Feb; 121(9):1524-33. PubMed ID: 23264589
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of PCR and ELISA assays for screening clinical trial subjects for replication-competent retrovirus.
Martineau D; Klump WM; McCormack JE; DePolo NJ; Kamantigue E; Petrowski M; Hanlon J; Jolly DJ; Mento SJ; Sajjadi N
Hum Gene Ther; 1997 Jul; 8(10):1231-41. PubMed ID: 9215740
[TBL] [Abstract][Full Text] [Related]
15. Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus.
van Lunzen J; Glaunsinger T; Stahmer I; von Baehr V; Baum C; Schilz A; Kuehlcke K; Naundorf S; Martinius H; Hermann F; Giroglou T; Newrzela S; Müller I; Brauer F; Brandenburg G; Alexandrov A; von Laer D
Mol Ther; 2007 May; 15(5):1024-33. PubMed ID: 17356541
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of recommendations for replication-competent retrovirus testing associated with use of retroviral vectors.
Wilson CA; Ng TH; Miller AE
Hum Gene Ther; 1997 May; 8(7):869-74. PubMed ID: 9143913
[TBL] [Abstract][Full Text] [Related]
17. Long-Term Safety Follow-Up of Subjects Previously Treated with Non-Replicating Retroviral Vector-Based Gene Therapies.
Mohanlal R; Qiu Y; Zheng M; Mirkou A; Sridharan K; Keir C
Mol Diagn Ther; 2016 Dec; 20(6):591-602. PubMed ID: 27435702
[TBL] [Abstract][Full Text] [Related]
18. Bacteria-free minicircle DNA system to generate integration-free CAR-T cells.
Cheng C; Tang N; Li J; Cao S; Zhang T; Wei X; Wang H
J Med Genet; 2019 Jan; 56(1):10-17. PubMed ID: 30030293
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy-based treatment for HIV-positive patients with malignancies.
Kang EM; De Witte M; Malech H; Morgan RA; Carter C; Leitman SF; Childs R; Barrett AJ; Little R; Tisdale JF
J Hematother Stem Cell Res; 2002 Oct; 11(5):809-16. PubMed ID: 12427287
[TBL] [Abstract][Full Text] [Related]
20. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Zhang E; Gu J; Xu H
Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
